Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination

Allen, Christopher Martin; Ramsamy, Shelby; Tarr, Alexander William; Tighe, Patrick Jason; Irving, William Lucien; Tanasescu, Radu; Evans, Jonathan Rhys

Abstract

Although SARS-CoV-2 vaccines are very safe, we report 4 cases of the bifacial weakness with paresthesias variant of Guillain–Barré syndrome (GBS) occurring within 3 weeks of vaccination with the Oxford–AstraZeneca SARS-CoV-2 vaccine. This rare neurological syndrome has previously been reported in association with SARS-CoV-2 infection itself. Our cases were given either intravenous immunoglobulin, oral steroids, or no treatment. We suggest vigilance for cases of bifacial weakness with paresthesias variant GBS following vaccination for SARS-CoV-2 and that postvaccination surveillance programs ensure robust data capture of this outcome, to assess for causality. ANN NEUROL 2021.

Citation

Allen, C. M., Ramsamy, S., Tarr, A. W., Tighe, P. J., Irving, W. L., Tanasescu, R., & Evans, J. R. (2021). Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination. Annals of Neurology, 90(2), 315-318. https://doi.org/10.1002/ana.26144

• Journal Article Type: Article
• Acceptance Date: May 30, 2021
• Online Publication Date: Jul 2, 2021
• Publication Date: Aug 1, 2021
• Deposit Date: Nov 24, 2021
• Publicly Available Date: Jul 3, 2022
• Journal: Annals of Neurology
• Print ISSN: 0364-5134
• Electronic ISSN: 1531-8249
• Publisher: Wiley
• Peer Reviewed: Peer Reviewed
• Volume: 90
• Issue: 2
• Pages: 315-318
• DOI: https://doi.org/10.1002/ana.26144
• Public URL: https://nottingham-repository.worktribe.com/output/5789016
• Publisher URL: https://onlinelibrary.wiley.com/doi/10.1002/ana.26144